NCT00542529View on ClinicalTrials.gov

Phase I/II, Randomized, Double-Blind, Study of the Progenitor Cell Mobilizing Effects of Imprime PGG™ Injection Administered at Varied Dosing Regimens With G-CSF Versus G-CSF Alone

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 30, 2006

Study Completion Date

December 31, 2006

Conditions
Healthy
Interventions
BIOLOGICAL

Imprime PGG TM for Injection

Doses of 2.0 and 4.0 mg/kg intravenous Imprime PGG administered over 1-2 hr for up to 4 consecutive days

Sponsors

Lead Sponsor

HiberCell, Inc.
All Listed Sponsors
lead

HiberCell, Inc.

INDUSTRY